IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
← catalyst calendarNCT04086264 · readout ≤ 193 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
218actual
Sites
29
Countries
France, Germany, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-11-06 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2019-09-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia
Interventions
- Drug: Azacitidine — also filed as Vidaza, Decitabine
- Drug: IMGN632 — also filed as CD123-targeted ADC
- Drug: Venetoclax — also filed as Venclexta, Venclyxto
Primary outcomes
what the primary-completion date above is the date OFSafety and Tolerability
measured approximately 3 years
Preliminary antileukemia activity
measured approximately 20 months
Minimal Residual Disease Levels
measured approximately 18 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed